Invasive Meningococcal Disease in Hospitalized Children in Argentina, 2020-2024: Clinical, Epidemiologic and Molecular Findings From a Multicenter Active Surveillance Study.

Authors

Angela Gentile, Julia Bakir, Mara Noemí Maydana, Juan Carlos Morales, Gabriela Ensinck, Adriana Ernst, Luciana J Moreira, Pablo Andrés Melonari, Alejandro Santillán Iturres, Adriana Efron

Published in

The Pediatric infectious disease journal. Oct 23, 2026. Epub Oct 23, 2026.

Abstract

Invasive meningococcal disease (IMD) is a low-incidence but high-impact infection associated with substantial mortality and sequelae. Following MenACWY vaccine introduction into Argentina's National Immunization Program in 2017, updated data on residual disease burden are needed.
A multicenter active hospital-based surveillance study was conducted in 6 pediatric sentinel units in Argentina (January 2020-December 2024) in children younger than 15 years with suspected IMD. Cases were confirmed by culture and/or polymerase chain reaction from a normally sterile body site. Hospital discharge rates were calculated per 10,000 discharges. Whole-genome sequencing and genetic Meningococcal Antigen Typing System were used to characterize strains and estimate theoretical 4CMenB coverage.
Among 234,264 pediatric hospital discharges, 27 confirmed IMD cases were identified (overall rate: 1.2 per 10,000; 95% confidence interval, 0.8-1.7). Annual rates showed no consistent pattern between children younger than 2 years and those 2 years or older. The case-fatality rate was 14.8% (4/27); all deaths occurred in previously healthy children younger than 5 years and were associated with sepsis and a fulminant course (hospital stay ≤1 day). Of 20 cases with a determined capsular group, 19 (95%) were B and 1 (5%) was C; no capsular group Y or W cases were identified. Theoretical 4CMenB coverage by genetic Meningococcal Antigen Typing System was 77.3%, driven by ST-162 clonal complex predominance.
IMD in Argentina continues to predominantly affect young children and is associated with elevated case-fatality amid fulminant sepsis. Serogroup B predominates in the post-MenACWY era, and high estimated 4CMenB coverage supports evaluation of serogroup B vaccination as a complementary prevention strategy.

PMID:
42919450
Bibliographic data and abstract were imported from PubMed on 24 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.